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Sodium channelThe a-subunit of the cardiac voltage-gated sodium channel (NaV1.5) plays a central role in cardiomy-
ocyte excitability. We have recently reported that NaV1.5 is post-translationally modiﬁed by arginine
methylation. Here, we aimed to identify the enzymes that methylate NaV1.5, and to describe the role
of arginine methylation on NaV1.5 function. Our results show that protein arginine methyl transfer-
ase (PRMT)-3 and -5 methylate NaV1.5 in vitro, interact with NaV1.5 in human embryonic kidney
(HEK) cells, and increase NaV1.5 current density by enhancing NaV1.5 cell surface expression. Our
observations are the ﬁrst evidence of regulation of a voltage-gated ion channel, including calcium,
potassium, sodium and TRP channels, by arginine methylation.
Structured digital abstract:
PRMT5 physically interacts with Nav1.5 by ﬂuorescent resonance energy transfer (View interaction)
PRMT3 physically interacts with Nav1.5 by ﬂuorescent resonance energy transfer (View interaction)
Nav1.5 physically interacts with PRMT3 by anti tag coimmunoprecipitation (View interaction)
PRMT1 physically interacts with Nav1.5 by ﬂuorescent resonance energy transfer (View interaction)
Nav1.5 physically interacts with PRMT1 by anti tag coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac ion channels are essential for the generation of cardio-
myocyte action potentials (AP). The cardiac voltage-gated sodiumchannel is responsible for the sodium inward current that initiates
the AP, and consists of an a-subunit (NaV1.5), which is necessary
and sufﬁcient for the generation of sodium currents, and accessory
proteins [1]. The ﬁne regulation of NaV1.5 current is vital for proper
cardiac function, and single mutations in NaV1.5 can lead to cardiac
arrhythmia conditions [2].
NaV1.5 is predicted to be composed of four homologous do-
mains, DI to DIV, joined by interdomain linkers. Interdomain link-
ers, N and C termini of the protein are cytosolic, and are accessible
to post-translational modiﬁcations such as phosphorylation [3],
and ubiquitination [4] which modulate NaV1.5 function. Notewor-
thy, we have recently reported initial (40% sequence coverage)
mass spectrometry evidence that identiﬁed arginine methylation
(ArgMe) as a novel post-translational modiﬁcation of NaV1.5 [5].
ArgMe was observed in Arg residues within the interdomain linker
between DI and DII of NaV1.5 (LI–II).
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(PRMT), which transfer methyl groups from the cofactor S-adeno-
syl-L-methionine (SAM) to the protein, leading to mono- or dime-
thylated arginines [6]. In the latter case, methylation can be
asymmetric or symmetric [7]. To date, 9 PRMTs have been identi-
ﬁed in the human genome [8], namely PRMT1 to -9. PRMT1, -2, -3,
-4, -6 and -8 are Type I PRMT that produce monomethyl and asym-
metric dimethyl arginines [9]. PRMT5 is a Type II PRMT that pro-
duces monomethyl and symmetric dimethyl arginines [10], while
PRMT7 leads to monomethyl arginines only [11]. PRMT9 has not
been biochemically characterised to date. The addition of methyl
groups modiﬁes the shape of the arginine residue, turning it more
bulky and hydrophobic, and may block a potential hydrogen bond
donor.
Evidence indicating that NaV1.5 is modiﬁed by ArgMe has
opened new questions in the sodium channel ﬁeld. In this context,
we set ourselves to identify the PRMTs that mediate NaV1.5 ArgMe,
and to describe their effect on NaV1.5 function.2. Materials and methods
2.1. Plasmids
A pcDNA3 plasmid that encodes NaV1.5 as a FLAG fusion, which
has previously been described [12–14], was used in electrophysio-
logical, co-IP, and biotin pull-down experiments. For Förster reso-
nance energy transfer (FRET) measurements, a NaV1.5-CFP
construct, which localises to the endoplasmic reticulum in HEK
cells, was used [15].
PRMTs for in vitro methylation assays were cloned into pGEX or
Myc vectors. GST-PRMT1, -2, -3, -4, -6, and -7, as well as
Myc-PRMT5, have been described [11,16]. To perform methylation
studies in cells, FRET, co-IP, electrophysiological, and biotin pull-
down experiments, PRMT-YFP fusion proteins were produced.
PRMT1, -2, -3, -5, -6 and -7 were cloned from human cardiac cDNA
(the study was approved by the institutional ethical committee of
the Dr. Josep Trueta Hospital, Girona, Spain) into pcDNA3.1 (Invit-
rogen) as C-terminal YFP fusion proteins. PRMT4 could not be
ampliﬁed from cardiac cDNA and a plasmid template was used.
LI–II (NaV1.5 residues 416–711) was cloned into pcDNA3.1 as
LI–II-FLAG-YFP fusion. Plasmids for expression in Escherichia coli
were pETM15b (EMBL) in which LI–II or the C-terminal domain
(NaV1.5 residues 1773–2016) were cloned as N-terminal His-
tagged proteins.
For electrophysiological and FRET assays, HEK cells were trans-
fected using calcium phosphate precipitation. For all other experi-
ments, cells were transfected using GeneCellin (BioCellChallenge).2.2. Detection of methylated LI–II in cells
HEK cells were transiently transfected with the LI–II-FLAG-YFP
plasmid (2 lg), and harvested 30 h later. Soluble lysates were incu-
bated with a-GFP antibody (Abcam) coupled to protein A beads
(GE Healthcare). Immunoprecipitated proteins were detected with
a-FLAG (M2, Sigma), a-ASYM24, or a-SYM11 (Merck).
2.3. In vitro methylation assays
LI–II and the C-terminal domain of NaV1.5 were expressed in
E. coli as 6His fusions, and puriﬁed using Ni-NTA chromatogra-
phy. In vitro methylation assays were conducted as described
[17]. Recombinant GST-PRMT1, -2, -3, -4, -6 and -7 were expressed
and puriﬁed from E. coli. Myc-tagged human PRMT5 was expressed
and puriﬁed from HeLa cells. Reactions were done in the presenceof 0.5 lCi S-adenosyl-L-[methyl-3H]methionine (3H-SAM, GE
Healthcare) for 1 h at 30 C in a ﬁnal volume of 30 ll.
2.4. FRET between NaV1.5 and PRMTs
HEK cells expressing NaV1.5-CFP (0.5 lg plasmid) together with
the corresponding PRMT–YFP (1.5 lg plasmid), or YFP as a negative
control (0.5 lg plasmid), were grown for 24–48 h after transfec-
tion. For every NaV1.5/PRMT pair, 4 independent transfections
were done. In every measuring session, 5–10 negative controls
were measured in parallel. Cells were examined by confocal
microscopy on a LSM 710 (Zeiss, Jena, Germany) using a C-Apo-
chromat 40/1.2 NA water-immersion objective lens at room tem-
perature. FRET was calculated using the sensitised emission
method. Reported apparent FRET efﬁciencies (FRETapp) are the
mean ± S.E.M. of individual cell FRETapp values for a given
NaV1.5-CFP/PRMT–YFP pair.
2.5. Co-IP of PRMT1 and -3, with NaV1.5
HEK cells were transiently transfected with FLAG NaV1.5 (1 lg
plasmid), together with GFP (0.5 lg plasmid), or PRMT1-, or -3–
YFP (1.5 lg plasmid). Cells were lysed 48 h after transfection, and
NaV1.5 was immunoprecipitated (n = 3) using FLAG chromatogra-
phy (Sigma). PRMTs were detected using an a-GFP antibody (Ab-
cam), and NaV1.5 was detected using an a-NaV1.5 antibody
(Alomone).
2.6. Electrophysiological recordings
Sodium currents in HEK cells transiently expressing FLAG-
NaV1.5 (1.5 lg plasmid) together with the corresponding PRMT–
YFP (0.5 lg plasmid), were measured between 25 and 35 h after
transfection. The total number of independent transfections was
5 (PRMT3 and -5), 3 (PRMT1), or 2 (PRMT2, -4, and -7). The day
after transfection, SAM (0.15 mM, ﬁnal concentration) was added
to the medium, and sodium currents were measured at room tem-
perature. In every session, 3–10 negative controls (i.e. cells co-
expressing NaV1.5 and YFP) were measured in parallel.
Currents were obtained by patch clamp whole-cell recording
using an Axopatch 200B ampliﬁer (Molecular Devices). Activation
data at test potentials of 80 to +50 mV (in 5 or 10 mV steps) were
ﬁtted to a Boltzmann equation, of the form
g ¼ gmax=ð1þ exp½ðV1=2  VmÞ=sÞ, where g is the conductance, gmax
the maximum conductance, Vm the membrane potential, V1/2 the
voltage at which half of the channels are activated, and s the slope
factor. Inactivation data at test potentials of 140 to 30 mV (in 5
or 10 mV steps, for 250 ms) were ﬁtted to a Boltzmann equation of
the form I ¼ Imax=ð1þ exp½ðVm  V1=2Þ=sÞ, where I is the peak cur-
rent amplitude, Imax the maximum peak current amplitude, Vm the
membrane potential, V1/2 the voltage at which half of the channels
are inactivated, and s the slope factor. Kinetics of NaV1.5 inactiva-
tion were ﬁtted to a monoexponential function, from which time
constant s (inactivation) between 40 and 30 mV was estimated.
NaV1.5 recovery from inactivation data (at recovery times of
250 ls, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 250, 500, 1000 and
1900 ms at 120 mV) were ﬁtted to monoexponential functions
to determine recovery time constant s. All reported errors are
S.E.M.
2.7. Biotin pull-down of cell surface proteins
Biotin pull-down of FLAG-NaV1.5 was performed from tran-
siently transfected HEK cells (n = 2) and from a previously devel-
oped [5] cell line stably expressing FLAG-NaV1.5 (n = 2). Cells
were transfected with NaV1.5 (1 lg plasmid) together with YFP
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were treated with reactive biotin (Pierce) for 60 min at 4 C, and
lysed. Soluble fractions were incubated with neutravidin (Pierce)
overnight at 4 C. Pull-downs were probed with a-NaV1.5 antibody.
Protein bands were quantiﬁed using ImageJ (NIH).
2.8. Cardiac AP simulations
We used the ten Tusscher–Panﬁlov 2006 model [18]. The model
was modiﬁed to reproduce the observed changes in sodium cur-
rent density in cells overexpressing PRMT3 or -5. We multiplied
the fast sodium current by a factor of (1 + p), where p was 0.46
or 0.35 (PRMT3-, or -5-cardiomyocytes, respectively). Used proto-
cols were an adaptation of recently reported protocols to simulate
cardiac arrhythmias [19].
3. Results
3.1. LI–II is a substrate for Type I and Type II PRMTs
The linker between DI and DII (LI–II) of NaV1.5 is a hot-spot for
ArgMe within NaV1.5 [5]. To test an isolated LI-II protein as sub-
strate for PRMTs, we overexpressed LI–II in HEK cells. Antibodies
speciﬁc to asymmetric, and symmetric, dimethyl arginines recog-
nised LI–II (Fig. 1A), indicating that LI–II was a target for Type I
and Type II PRMTs.
To identify the PRMTs that methylate LI–II, we performed
in vitro methylation assays using recombinant PRMTs and
3H-SAM. We puriﬁed untagged LI–II, from E. coli (Fig. 1B), as sub-
strate. The C-terminal domain of NaV1.5 was included as negative
control. We screened all known PRMTs excluding PRMT8, which is
speciﬁcally expressed in the central nervous system [20], and
PRMT9, which has not been characterised [9]. Consistent with
our ﬁndings in cells, we observed methylation of LI–II by Type I
(PRMT1, -3, -4 and -6), and Type II (PRMT5) PRMTs (Fig. 1C).
PRMT5 showed weak activity towards LI–II in vitro, but the fact that
LI–II was symmetrically dimethylated in cells strongly indicates
that PRMT5, the only Type II PRMT [9,10,21], methylates NaV1.5.
The observation that PRMT1 methylates the C-terminal domain
was unexpected. Methylated protein bands at lower molecularFig. 1. LI–II is a substrate for PRMTs. (A) LI–II-FLAG-YFP recognised by antibodies against sy
are in kDa. Expected size: 61 kDa. (B) Expression of LI–II and the C-terminal domain of N
weights are in kDa.weight most likely corresponded to degradation products, which
might serve as preferred recognition motifs.
3.2. NaV1.5 interacts with PRMT1, -3 and -5
Next, we screened for interactions between full length NaV1.5
and PRMTs. We observed signiﬁcant FRET efﬁciency (FRETapp) be-
tween NaV1.5–CFP and PRMT1–, -3–, or -5–YFP, compared to con-
trol (YFP) cells, and cells co-expressing PRMT2, -4, and -7 (Fig. 2A
and B, and Supplementary Fig. S1). PRMT6 was discarded for later
experiments, because it localised exclusively to the cell nucleus
(not shown), in agreement with previous reports [16,22–24].
To validate our FRET results, we performed co-IP experiments in
HEK cells. After IP of NaV1.5 by FLAG-afﬁnity, we detected co-IP of
PRMT1– and -3–YFP (Fig. 2C). PRMT5 was excluded from FLAG co-
IP experiments, as it cross-reacts with a-FLAG antibodies [9].
3.3. NaV1.5 cell surface expression is increased by PRMT3 and -5
To address the effect of PRMTs on NaV1.5 electrophysiology, we
co-transfected HEK cells with NaV1.5 and PRMTs. We observed in-
creased NaV1.5 current density (in pA/pF) in cells co-expressing
PRMT3 (102 ± 10), or PRMT5 (95 ± 9), compared to control cells
(70 ± 6), (Fig. 3A–C). NaV1.5 current density in cells co-expressing
PRMT1 (77 ± 7) was not signiﬁcantly higher than in control cells.
NaV1.5 voltage-dependent activation and inactivation, recovery
from inactivation (Supplementary Table S1), and kinetics of inacti-
vation (Supplementary Fig. S2) were unchanged in all cases.
We hypothesised that the observed increase in NaV1.5 current
density was due to higher NaV1.5 cell surface expression. Biotin
pull-down experiments revealed ca. 30% increased NaV1.5 cell sur-
face expression in cells co-expressing PRMT3 or -5, compared to
control, and PRMT1 cells (Fig. 3, D–F), in reasonable agreement
with electrophysiological ﬁndings (46% and 35% higher current
density in the presence of PRMT3 and -5, respectively).
3.4. Increased NaV1.5 ArgMe changes cardiac AP dynamics in silico
To extend our ﬁndings to a cardiac context, we generated com-
puter cardiomyocyte AP simulations. We considered controlmmetric (a-SYM), and asymmetric (a-ASYM) dimethyl arginine. Molecular weights
aV1.5 (Ctd) in E. coli (marked with stars). (C) In vitro methylation assays. Molecular
Fig. 2. NaV1.5 interacts with PRMT1, -3 and -5. (A) Representative cells co-expressing NaV1.5-CFP and YFP (control), PRMT1–, -3–, or -5–YFP. Shown: transmission image
including CFP and YFP ﬂuorescence; CFP and YFP channels at respective excitation and emission; and corrected FRETapp image. Scale bars (of 40 lm length) represent low
(red) to high (blue) FRETapp; and low (white) to high (black) CFP or YFP intensity. (B) FRETapp between NaV1.5–CFP and PRMT–YFP. Over each bar the number of evaluated cells
is indicated. ⁄Signiﬁcant (P < 0.002 ANOVA test). (C) Representative gel picture (n = 3) before (input), and after IP of NaV1.5. PRMT1–YFP (67 kDa) and -3–YFP (86 kDa), but not
YFP neither actin, co-IP with NaV1.5.
3162 P. Beltran-Alvarez et al. / FEBS Letters 587 (2013) 3159–3165cardiomyocytes, as well as PRMT3- or -5-cardiomyocytes with 46%
or 35% (respectively), higher sodium current density. We per-
formed 6000 cycles at 60 beats per minute (bpm), and then in-
creased pacing abruptly to ca. 150 bpm. Under these conditions,
control cardiomyocytes led to alternans (Fig. 4), while PRMT3-
and -5-cardiomyocytes generated APs at pacing rate, the duration
of which was stabilised after 10 stimuli.
4. Discussion
Recently, we have revealed ArgMe as a novel NaV1.5 post-trans-
lational modiﬁcation [5]. Now, we present the ﬁrst systematicanalysis of the effect of individual PRMTs on the function of a volt-
age-gated ion channel, and demonstrate that PRMT3 and -5 in-
crease NaV1.5 cell surface expression. Future work will elucidate
whether this is due to facilitated trafﬁcking to the plasma mem-
brane (a proposed effect of NaV1.5 phosphorylation [3]), or ex-
tended residence time at the cell surface (ArgMe by PRMT3 may
inhibit ubiquitination and thereby proteolysis of target proteins
[25]).
PRMT1 methylated LI–II, and interacted with NaV1.5 in cells, but
did not regulate NaV1.5 cell surface expression under our experi-
mental conditions. This may be related to the observation that
PRMT1 was the only PRMT that methylated the C-terminal domain
Fig. 3. NaV1.5 cell surface expression is increased by PRMT3 and -5. (A) NaV1.5 peak current density at 10 mV in cells co-expressing PRMTs. Over each bar the number of
evaluated cells is indicated. ⁄Signiﬁcant (P < 0.01 ANOVA test). (B) Representative NaV1.5 currents in control (YFP), PRMT3 or -5 cells. (C) I–V curves in control (YFP) cells,
PRMT1, -3 or -5 cells. (D) Representative gel picture (n = 4) after biotin pull-down from non-transfected (CTL), control (YFP), PRMT1, -3 or -5 cells. The Na+/K+ ATPase a
subunit was probed as a loading control for pull-downed samples. Actin was included as marker for cytosolic proteins contamination in biotin pull-downs (not observed).
Shown between brackets, quantiﬁcation of signal intensity of NaV1.5 bands. (E) Bar plot showing ratio of NaV1.5/ATPase intensities in cells co-expressing PRMT1, -3 or -5,
normalised to control (YFP). Note that NaV1.5 signal intensity in PRMT3 and -5 was 2.3 and 2.1 times higher, respectively, than control experiments. ⁄Signiﬁcant (P < 0.05
unpaired t-Student test). (F) Calibration of Western blot signal for NaV1.5 and ATPase under our experimental conditions. NaV1.5 detection was not in the linear range:
doubling the loading doubled ATPase signal, but increased NaV1.5 signal by a factor of 7.7. We estimate that the observed increase in NaV1.5 signal by a factor of 2.3 and 2.1
corresponds to ca. 30% and 27% (PRMT3 and -5, respectively) higher NaV1.5 cell surface expression.
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idues on NaV1.5 cell surface expression, needs be described by fur-
ther work. PRMT2, -4, -6 and -7 are most likely not relevant to full
length NaV1.5, and we relate the observed in vitro methylation of
LI–II by PRMT4 and -6 to the suitability of an isolated LI–II protein
as substrate for ArgMe.The observation of an effect on NaV1.5 cell surface expression
upon co-expression of PRMT3 and -5 suggests that PRMT concen-
tration is an important factor to regulate levels of NaV1.5 ArgMe.
In the human heart, where NaV1.5 is modiﬁed by ArgMe [5],
expression of NaV1.5, PRMT3 and -5 may be dysregulated e.g. in
cardiac disease [26,27], which in turn may affect NaV1.5 ArgMe.
Fig. 4. Increased NaV1.5 ArgMe changes AP dynamics in silico. APs of control, PRMT5- and -3-cardiomyocytes paced at ca. 150 beats per minute (bpm) after 6000 conditioning
pulses at 60 bpm, the last two of which are shown. Arrows indicate pacing.
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NaV1.5 ArgMe sustained action potentials at high pacing when
control cardiomyocytes did not. Validation of our data, which have
been obtained in accepted (but heterologous) systems, in the car-
diac pathophysiology, will further the relevance of NaV1.5 ArgMe.
In conclusion, the observation of NaV1.5 regulation by PRMT3
and -5 contributes to growing evidence that NaV1.5 is modulated
by multiple processes [28], continues to expand ArgMe to non-his-
tone proteins [21], and should trigger studies of ArgMe in other
members of the voltage-gated ion channel superfamily, which con-
sists of 143 proteins [29].
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